@sallik74

Check with your team. I research above on Chat GPat but always verify with your hematologist/oncologist.

What Tecvayli is
• A bispecific antibody (BCMA × CD3) that redirects your own T-cells to attack myeloma cells
• Given as a subcutaneous injection
• Designed for more advanced disease settings

⸻

📊 Where Tecvayli is approved (as of 2026)
• Initially (2022): for heavily pretreated relapsed/refractory multiple myeloma (after ≥4 prior therapies) 
• Updated (March 2026): now also approved earlier (after ≥1 prior line) in combination with daratumumab 

👉 Key point:
All approvals are for active multiple myeloma that has already been treated, not early or smoldering disease.

⸻

🚫 Why it’s NOT used in smoldering myeloma

Smoldering myeloma is treated very differently:
• Goal = delay progression, not aggressive immune activation
• Many patients are observed or treated with lower-intensity approaches
• Tecvayli:
• Has significant immune effects (cytokine release syndrome, infection risk)
• Is considered too intensive for early disease at this time

⸻

🔬 Is it being studied earlier? (This is where it gets interesting)

Yes—this is likely why it’s on your radar.

There are ongoing clinical trials looking at:
• Tecvayli in earlier lines of myeloma
• Combinations like Tecvayli + daratumumab (already moving earlier)
• Potential future use in high-risk smoldering myeloma

But:
👉 No standard-of-care use yet for SMM

@sallik74
Diagnosed with high risk SMM in August 2025. Have just started Darzalex FasPro (had three infusions so far). So far all well, no side effects or otherwise. Have you discussed this treatment with your oncologist?